← Leaderboards
Candice J Perkins
State University New York Stony Brook
$50,927
Attributed
$50,927
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $14.3K · FY2005–09$20K$15K$10K$5K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$50,927 · 12
By mechanism
M01$50,927 · 12
Top collaborators
No co-investigators on record.
Most similar at State University New York Stony Brook
Same institution · by research overlap
- Wolfgang W Quitschke$1,773,174
- Christopher Christodoulou$180,126
- Oded Gerber$78,415
- John K Robinson$1,538,482
- Stephen A Vitkun$5,272
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelStrokeGrantSourceUnited States National Institutes Of HealthFundingInstitutionSafetyClinical ResearchHuman SubjectSimvastatinCardiovascular Disorder RiskPurposeDosePharmaceutical PreparationsMyocardial InfarctionClinical TrialsEnergy TransferCholesterolEffectivenessCellsCondition
Grant awards (13)
DESSTINI-DOSE ESCALATION SAFETY STUDY IN NORMAL INDIVIDUALS TAKING POLYMVA$6,848
M01 · FY2009 · RR · contact PI
DESSTINI-DOSE ESCALATION SAFETY STUDY IN NORMAL INDIVIDUALS TAKING POLYMVA$3,030
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZEIMER'S DISEA$209
M01 · FY2008 · RR · contact PI
POLY MVA UTILIZED AS NEUROPROTEIN IN CHRONIC HYPERTENSION$11,173
M01 · FY2007 · RR · contact PI
TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZEIMER'S DISEASE$2,140
M01 · FY2007 · RR · contact PI
AN OPEN-LABEL, PILOT STUDY OF SAFETY AND TOLERABILITY$951
M01 · FY2007 · RR · contact PI
POLY MVA UTILIZED AS NEUROPROTEIN IN CHRONIC HYPERTENSION$7,319
M01 · FY2006 · RR · contact PI
TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE$3,467
M01 · FY2006 · RR · contact PI
AN ANALYSIS OF CEREBRAL VASCULAR RESERVE IN PATIENTS WITH ANGIOPLASTY$1,541
M01 · FY2006 · RR · contact PI
TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE$4,083
M01 · FY2005 · RR
VISP$5,272
M01 · FY2004 · RR
Trial of Simvastatin to Slow the Progression of Alzheime$4,518
M01 · FY2004 · RR
An Analysis of Cerebral Vascular Reserve in Patients with Angioplasty$376
M01 · FY2004 · RR